| Total number of participants1 |
| Treatment group | No AE | Mild event | Moderate event | Serious event | Between-group comparison |
| Lovastatin | 1 | 10 | 1 | 0 | 0.3734 |
| Placebo | 3 | 9 | 4 | 0 | |
| Total number of adverse events2 |
| Treatment Group | Mild event | | Moderate event | Serious event | Between-group comparison |
| Lovastatin | 31 | | 1 | 0 | 0.2488 |
| Placebo | 38 | | 7 | 0 | |
| Total number of adverse events: relationship3 |
| Treatment group | Not related | | Unlikely | Probably related | Between-group comparison |
| Lovastatin | 10 | | 12 | 10 | 0.8172 |
| Placebo | 14 | | 21 | 20 | |
- 1Number of participants experiencing a certain severity of an adverse event where each participant is counted only once at the highest level of severity for the event
- 2Total number of adverse events experiencing a certain severity of an adverse event, including recurrence of same adverse event
- 3Total number of adverse events determined to be related to study drug (lovastatin), including recurrence of same adverse event
